Gemcitabine-cisplatin chemotherapy plus anti-PD-L1 therapy reinvigorates antitumor immune response by reprogramming the intrahepatic cholangiocarcinoma microenvironment.

ABSTRACT:

Purpose

Gemcitabine-cisplatin chemotherapy combined with anti-PD-L1 (GCP) therapy exhibits potent antitumor efficacy in patients with advanced intrahepatic cholangiocarcinoma (ICC). We aim to determine the intra-tumoral changes of ICC following GCP therapy in this study.

Methods

We performed single-cell RNA-seq (scRNA-seq) of 15 samples from 3 ICC patients receiving GCP therapy. The major findings of scRNA-seq analyses were further validated via analyzing the bulk RNA-seq data from the FU-iCCA cohort (n=244), as well as performing immunohistochemistry (IHC) and multiplex immunofluorescence (mIF) staining on a treatment-naïve tissue microarray (TMA) cohort (n=89) and a GCP-treated cohort (n=32).

Results

For the scRNA-seq cohort, two patients achieved tumor regression a

SUBMITTER: Song Y 

PROVIDER: S-EPMC12706460 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature